Loss from operations (54,747) (94,423) (230,546) (316,952)
Change in fair
value of
derivative tranche
liability - - - 10,291
Interest income 7,535 10,502 25,132 20,486
Other income
(expense), net (1,336) (19) 36,221 (254)
Net loss $ (48,548) $ (83,940) $ (169,193) $ (286,429)
---------- ---------- ---------- ----------
Other comprehensive
gain (loss)
Unrealized gain
(loss) on
short-term
marketable
securities, net 551 (94) 222 36
Total other
comprehensive
gain (loss) $ 551 $ (94) $ 222 $ 36
---------- ---------- ---------- ----------
Net loss and other
comprehensive loss $ (47,997) $ (84,034) $ (168,971) $ (286,393)
========== ========== ========== ==========
Net loss per share
attributable to
common
stockholders, basic
and diluted $ (0.49) $ (0.87) $ (1.71) $ (4.68)
Weighted-average
common shares
outstanding, basic
and diluted 99,835,707 96,872,747 98,973,518 61,138,105
========== ========== ========== ==========
ACELYRIN, INC.
Selected Consolidated Balance Sheet Data
(unaudited)
(in thousands)
September 30, December 31,
------------------------ ------------------------
2024 2023
---------------- ----------------
Cash and cash
equivalents $ 216,326 $ 218,097
Short-term
marketable
securities 346,047 503,229
Total assets 618,310 742,690
Total liabilities 90,029 86,353
Accumulated deficit (657,912) (488,719)
ACELYRIN Contacts:
Tyler Marciniak
Vice President of Investor Relations and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com
(END) Dow Jones Newswires
November 13, 2024 16:00 ET (21:00 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。